I
Isobel J Fetter
Researcher at Harvard University
Publications - 13
Citations - 860
Isobel J Fetter is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Colorectal cancer. The author has an hindex of 6, co-authored 12 publications receiving 341 citations.
Papers
More filters
Journal ArticleDOI
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers.
Aparna Raj Parikh,Ignaty Leshchiner,Liudmila Elagina,Lipika Goyal,Chaya Levovitz,Giulia Siravegna,Dimitri Livitz,Kahn Rhrissorrakrai,Elizabeth E. Martin,Emily E. Van Seventer,Megan Hanna,Kara Slowik,Filippo Utro,Christopher J. Pinto,Alicia Wong,Brian P. Danysh,Ferran Fece de la Cruz,Isobel J Fetter,Brandon Nadres,Heather A. Shahzade,Jill N. Allen,Lawrence S. Blaszkowsky,Jeffrey W. Clark,Bruce J. Giantonio,Janet E. Murphy,Ryan D. Nipp,Eric Roeland,David P. Ryan,Colin D. Weekes,Eunice L. Kwak,Jason E. Faris,Jennifer Y. Wo,François Aguet,Ipsita Dey-Guha,Mehlika Hazar-Rethinam,Dora Dias-Santagata,David T. Ting,Andrew X. Zhu,Theodore S. Hong,Todd R. Golub,Todd R. Golub,Todd R. Golub,A. John Iafrate,Viktor A. Adalsteinsson,Alberto Bardelli,Laxmi Parida,Dejan Juric,Gad Getz,Ryan B. Corcoran +48 more
TL;DR: Direct prospective comparison of circulating tumor DNA and tissue biopsy sequencing shows the superiority of liquid biopsies for capturing clinically relevant alterations mediating resistance to targeted therapies in cancer patients.
Journal ArticleDOI
TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma
Lipika Goyal,Lei Shi,Leah Y. Liu,Ferran Fece de la Cruz,Jochen K. Lennerz,Srivatsan Raghavan,Srivatsan Raghavan,Ignaty Leschiner,Liudmila Elagina,Giulia Siravegna,Raymond W.S. Ng,Raymond W.S. Ng,Phuong Vu,Krushna C. Patra,Supriya K. Saha,Raul N. Uppot,Ronald S. Arellano,Stephanie Reyes,Takeshi Sagara,Sachie Otsuki,Brandon Nadres,Heather A. Shahzade,Ipsita Dey-Guha,Isobel J Fetter,Islam Baiev,Emily E. Van Seventer,Janet E. Murphy,Cristina R. Ferrone,Kenneth K. Tanabe,Vikram Deshpande,James J. Harding,Rona Yaeger,Robin Kate Kelley,Alberto Bardelli,A. John Iafrate,William C. Hahn,William C. Hahn,Cyril H. Benes,David T. Ting,Hiroshi Hirai,Gad Getz,Gad Getz,Dejan Juric,Andrew X. Zhu,Ryan B. Corcoran,Nabeel Bardeesy +45 more
TL;DR: It is reported that the irreversible pan-FGFR inhibitor, TAS-120, demonstrated efficacy in four patients with FGFR2-fusion-positive ICC who developed resistance to BGJ398 or Debio1347 and suggests that strategic sequencing of FGFR inhibitors, guided by serial biopsies and ctDNA, may prolong the duration of benefit from FGFR inhibition in patients withFGFR2 fusion- positive ICC.
Journal ArticleDOI
Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer.
Aparna Raj Parikh,Emily E. Van Seventer,Giulia Siravegna,Anna Hartwig,Ariel Jaimovich,Yupeng He,Katie Kanter,Madeleine Fish,Kathryn Fosbenner,Benchun Miao,Susannah T. Phillips,John H. Carmichael,Nihaarika Sharma,Joy X. Jarnagin,Islam Baiev,Yojan S. Shah,Isobel J Fetter,Heather A. Shahzade,Jill N. Allen,Lawrence S. Blaszkowsky,Jeffrey W. Clark,Jon Dubois,Joseph W. Franses,Bruce J. Giantonio,Lipika Goyal,Samuel J. Klempner,Ryan D. Nipp,Eric Roeland,David P. Ryan,Colin D. Weekes,Jennifer Y. Wo,Theodore S. Hong,Liliana Bordeianou,Cristina R. Ferrone,Motaz Qadan,Hiroko Kunitake,David H. Berger,Rocco Ricciardi,James C. Cusack,Victoria M. Raymond,AmirAli Talasaz,Genevieve M. Boland,Ryan B. Corcoran +42 more
TL;DR: Benton et al. as mentioned in this paper evaluated a plasma-only ctDNA assay integrating genomic and epigenomic cancer signatures to enable tumor-uninformed MRD detection, which demonstrated favorable sensitivity and specificity for recurrence.
Journal ArticleDOI
Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers.
Aparna Raj Parikh,Amirkasra Mojtahed,Jaime L. Schneider,Katie Kanter,Emily E. Van Seventer,Isobel J Fetter,Ashraf Thabet,Madeleine Fish,Bezaye Teshome,Kathryn Fosbenner,Brandon Nadres,Heather A. Shahzade,Jill N. Allen,Lawrence S. Blaszkowsky,David P. Ryan,Bruce J. Giantonio,Lipika Goyal,Ryan D. Nipp,Eric Roeland,Colin D. Weekes,Jennifer Y. Wo,Andrew X. Zhu,Dora Dias-Santagata,A. John Iafrate,Jochen K. Lennerz,Theodore S. Hong,Giulia Siravegna,Nora Horick,Jeffrey W. Clark,Ryan B. Corcoran +29 more
TL;DR: Serial ctDNA monitoring may provide early indication of response to systemic therapy in patients with metastatic gastrointestinal cancer prior to radiographic assessments and may outperform standard tumor markers, warranting further evaluation.
Journal ArticleDOI
FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma.
James M. Cleary,Srivatsan Raghavan,Qibiao Wu,Yvonne Y. Li,Liam F. Spurr,Hersh Gupta,Douglas A. Rubinson,Isobel J Fetter,Jason L. Hornick,Jonathan A. Nowak,Giulia Siravegna,Lipika Goyal,Lei Shi,Lauren K. Brais,Maureen Loftus,Atul B. Shinagare,Thomas A. Abrams,Thomas E. Clancy,Jiping Wang,Anuj K. Patel,Franck Brichory,Anne Vaslin Chessex,Ryan J. Sullivan,Rachel B. Keller,Sarah L. Denning,Emma R. Hill,Geoffrey I. Shapiro,Anna Pokorska-Bocci,Claudio Zanna,Kimmie Ng,Deborah Schrag,Pasi A. Jänne,William C. Hahn,Andrew D. Cherniack,Ryan B. Corcoran,Matthew Meyerson,Antoine Daina,Vincent Zoete,Nabeel Bardeesy,Brian M. Wolpin +39 more
TL;DR: FGFR2 EIDs are revealed as an alternative mechanism of FGFR2 activation in IHCC that predict sensitivity to FGFR inhibitors in the clinic and reveal the genomic landscape by anatomic site within the biliary tree.